Bone tumor

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Retrieved on: 
Friday, November 17, 2023
FDA, Pharmaceutical, Health, Medicine, Vomiting, Digoxin, Osteoporosis, Woman, Urine, Antares, NYSE, Bone disease, Calcium, Spine, Prednisone, Constipation, Allergy, History, IQVIA, Patient, Arthralgia, Medication, TEVA, Fracture, Muscle weakness, System, Blood, Tongue, Vitamin, Bone tumor, Nausea, Kidney, Pain, Swelling, Osteosarcoma, Skin, Rat, TASE, Injection, Face, Blood pressure, Generic drug, Dietary supplement, Pharmaceutical industry, Vaccine, Birth control, Injection moulding, Medical imaging, Poultry farming, Phosphorus, Teriparatide, Teva

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.

Key Points: 
  • Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
  • Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • Teva’s generic equivalent of Forteo® (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device.
  • Teriparatide injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.

Global Prosthetics Market Projected to Reach $2.30 Billion by 2023: A Comprehensive Analysis of Key Drivers and Challenges - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Robotics, Medical Devices, Health, Technology, General Health, Biotechnology, 3D, Willowwood Arboretum, Ageing, Incidence, Bone tumor, Obesity, Use, Prevalence, Diabetes, Trauma, Hanger, Inc., Artificial intelligence, Quality of life, Injury, Growth, Life expectancy, COVID-19, Hospital, Accident, Ankle, Investment, Patient, Dentistry, Medical device, Prosthesis

The global prosthetics market is divided into four regions:

Key Points: 
  • The global prosthetics market is divided into four regions:
    North America leads the market, driven by an increasing prevalence of orthopedic injuries, growing trauma cases, and the rise in obesity contributing to diabetes.
  • Europe presents strong growth potential, primarily due to rising life expectancy, an aging population, and an increase in road injuries.
  • The COVID-19 pandemic initially posed challenges to the prosthetics market, with disruptions in supply chains and restrictions on elective medical procedures.
  • The global prosthetics market is moderately concentrated, with leading companies pursuing growth strategies such as mergers, acquisitions, collaborations, and agreements.

WebMD Announces 16th Annual 2023 Health Heroes

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Neuroscience, COVID-19, Osteochondrodysplasia, Skull, Bias, Family, The Children's Hospital, Machine learning, MS, Headache, COVID, Driving Force, Sickle cell disease, Rickets, Hospital, Bone tumor, Heart Trouble (album), CDC, Genetics, Disease, WHO, Patient, World Health Organization, Chordoma, Movement, Education, Long, CRISPR, HCA Healthcare, Clinical trial, Duke Cancer Institute, Public policy, Duke University, Genetic disorder, King Fahad Specialist Hospital Dammam, Bangladesh Technical Education Board, Jansen, Tissue, Volunteering, Korea Disease Control and Prevention Agency, Grey, Child, National Institutes of Health, Sarah Cannon Research Institute, Life, WebMD, Research, NIH, Cognitive science, Nursing, Pharmaceutical industry, Vaccine, MD, Long COVID

NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.

Key Points: 
  • NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.
  • "This year's Health Heroes are not only doing amazing things but they also have data or other measurable results that demonstrate the impact of their work," said Dr. John Whyte, Chief Medical Officer of WebMD.
  • With their findings in hand, they began meeting with public health leadership at the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and World Health Organization (WHO) to forge a path toward more research on Long COVID.
  • For additional information on the 2023 WebMD Health Heroes, click here: https://www.webmd.com/healthheroes/default.htm

Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health

Retrieved on: 
Monday, April 3, 2023
Osteoarthritis, Extremities, CELU, Placenta, CDRH, Therapy, Prevalence, Bone tumor, Classification, Osteoporosis, Pelvis, FDA Center for Devices and Radiological Health, Scar, Instituto de Biologia Molecular e Celular, Research, AMR, Cell, Regenerative medicine, Fibrosis, Osteomyelitis, Combination, OCP, FUSE, Chemokine, Growth, Cytokine, Device, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Scoliosis, Wound healing, Pharmaceutical industry, Medical device

FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Combination Products (OCP) completed its preliminary product classification and jurisdictional assessment of Celularity’s investigational FUSE Bone Void Filler (“FUSE”). FUSE is being developed for use as a passive osteoconductive bone filler in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects that are not dependent on chemical action to mediate an effect.

Key Points: 
  • The OCP reviewed information provided by Celularity in its Pre-RFD, on the basis of which the OCP made a preliminary assessment that it agrees with Celularity’s recommendation that FUSE should be classified as a device regulated by the FDA’s Center for Devices and Radiological Health (CDRH).
  • Based on the OCP’s preliminary assessment, Celularity now intends to submit a 510(k) notification for FUSE in early 2024.
  • FUSE has been designed as an absorbable, biocompatible, and osteoconductive in nature bone void filler.
  • Following placement in the bony void or gap, FUSE resorbs and is replaced with bone during the healing process.

Global Arthroscopy Devices Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Medical Devices, Health, Shoulder, Joint, Jaw, Spine, Wrist, Rheumatoid arthritis, MI, Ankle, Arthroscopy, Sports medicine, Elbow, DSM-IV codes, Hip, Tendinopathy, Bone tumor, Growth, Knee, Prevalence, COVID-19, HD, Osteoarthritis, Medical imaging, Medical device

Arthroscopy devices refer to various medical equipment and tools that are used to visualize, examine and conduct therapeutic interventions inside various joints of the body.

Key Points: 
  • Arthroscopy devices refer to various medical equipment and tools that are used to visualize, examine and conduct therapeutic interventions inside various joints of the body.
  • Some of the commonly used devices during arthroscopy include arthroscope, implants, fluid management systems, radiofrequency systems, visualization systems, etc.
  • The publisher provides an analysis of the key trends in each sub-segment of the global arthroscopy devices market report, along with forecasts at the global, regional and country level from 2022-2027.
  • Our report has categorized the market based on device type, arthroscopy type and end-user.

$6.7 Billion Worldwide Arthroscopy Devices Industry to 2027 - Key Players Include Arthrex, CONMED, Johnson & Johnson Services and Karl Storz

Retrieved on: 
Monday, January 30, 2023
Zimmer Biomet, Bone tumor, Smith & Nephew, Jaw, Rheumatoid arthritis, Spine, United States v. Arthrex, Inc., Hip, Ankle, Medtronic, Shoulder, Sports medicine, COVID-19, Wrist, Osteoarthritis, Arthroscopy, Elbow, Tendinopathy, DSM-IV codes, Prevalence, HD, Stryker Corporation, MI, Joint, Knee, Video game, Semiconductor, Medical imaging, Pharmaceutical industry, Potash, Growth

Looking forward, the publisher expects the market to reach US$ 6.7 Billion by 2027, exhibiting a CAGR of 8.09% during 2021-2027.

Key Points: 
  • Looking forward, the publisher expects the market to reach US$ 6.7 Billion by 2027, exhibiting a CAGR of 8.09% during 2021-2027.
  • Arthroscopy devices refer to various medical equipment and tools that are used to visualize, examine and conduct therapeutic interventions inside various joints of the body.
  • Some of the commonly used devices during arthroscopy include arthroscope, implants, fluid management systems, radiofrequency systems, visualization systems, etc.
  • What is the structure of the global arthroscopy devices market and who are the key players?

US Bone Cancer Market and Competitive Landscape 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 14, 2022
Health, Oncology, Research, Competitive landscape, Epidemiology, Bone tumor, Dietary supplement

The "US Bone Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Bone Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report US Bone Cancer Market and Competitive Landscape Highlights - 2022, provides comprehensive insights into Bone Cancer pipeline products, Bone Cancer epidemiology, Bone Cancer market valuations and forecast, Bone Cancer drugs sales and competitive landscape in the US.
  • Bone Cancer pipeline: Find out the products in clinical trials for the treatment of Bone Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Bone Cancer drugs: Identify key products marketed and prescribed for Bone Cancer in the US, including trade name, molecule name, and company
    Bone Cancer market valuations: Find out the market size for Bone Cancer drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Bone Cancer drugs market share: Find out the market shares for key Bone Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Bone Cancer products

OrthoPediatrics Corp. Announces Distribution Agreement with 3D-Side

Retrieved on: 
Wednesday, July 13, 2022
Technology, Trauma, Elective surgery, Surgeon, Communication, Customer benefit package, Solution, MRI, United, CT, Osteotomy, Bone tumor, Patient, Deformity, CEO, Heart, GLOBE, Scoliosis, Orthopediatrics, Hospital, DNA, Partnership, Medical imaging, Dentistry

This commercial agreement grants OrthoPediatrics exclusive distribution rights of the 3D-CUT-OSTEO osteotomy guide in the United States leading pediatric hospitals in addition to certain international markets in the future.

Key Points: 
  • This commercial agreement grants OrthoPediatrics exclusive distribution rights of the 3D-CUT-OSTEO osteotomy guide in the United States leading pediatric hospitals in addition to certain international markets in the future.
  • We are excited to enter this relationship with 3D-Side to provide our pediatric orthopedic customers access to the 3D-CUT products.
  • Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics.
  • OrthoPediatrics currently markets 37 surgical systems that serve three of the largest categories within the pediatric orthopedic market.

Children’s National Hospital uses cutting-edge technology to perform first ever non-invasive brain tumor surgery

Retrieved on: 
Wednesday, February 9, 2022
GLOBE, Neurology, Radiology, Microbubble, Neoplasm, Brain, Radiation, Hamartoma, Essential tremor, NF, Spinal cord, Bone tumor, Neuro, Clinical trial, Center of excellence, Program, Risk, Oncology, FDA, Hospital, Patient, Technology, Neuroscience, Behavioral medicine, Adult, Immunotherapy, Traffic barrier, Epilepsy, Center, Movement disorders, HIFU, Travel, FUS, Elective surgery, Neurofibromatosis, Dentistry, Medicine, Medical imaging, Neurosurgery

Washington D.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Childrens National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF).

Key Points: 
  • Washington D.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Childrens National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF).
  • Childrens National is one of the first pediatric hospitals in the nation to use HIFU for neuro-oncology patients.
  • Its also the first hospital in the world to use it to treat a pediatric patient with NF.
  • In 2015, Childrens National doctors became the first in the U.S. to use MR-HIFU to treat pediatric osteoid osteoma a benign, but painful bone tumor.

AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Retrieved on: 
Tuesday, November 30, 2021
Giant, Patient, Organization, Leiden University Medical Center, Tenosynovial giant cell tumor, Idiopathic pulmonary fibrosis, Cell, Oncology, CSF1, KOL, Sarcoma, Pharmacogenomics, Doctor of Philosophy, National Wilms Tumor Study Group, Advisory Committee on Immunization Practices, Bone tumor, Pain, Quality of life, Research, Risk, Disability, IPF, Adult, Incidence, Health, Infection, Administration, GLOBE, Q&A, Macrophage, GIST, EPOS, Stromal cell, EORTC, Principal investigator, CSF1R, LUMC, Department, Adolescence, Vaccine, Medicine, Medical imaging

REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will host a key opinion leader (KOL) webinar on AMB-05X and its potential as a new standard of care in the treatment of tenosynovial giant cell tumor (TGCT).

Key Points: 
  • Professor Gelderblom has served as a Principal Investigator on multiple clinical trials for tenosynovial giant cell tumor (TGCT) and is currently a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • Prof. van de Sande has participated in numerous tenosynovial giant cell tumor (TGCT) trials and is a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT).
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).